I'm joined this week by Brian Finrow, CEO of Lumen Bioscience, who thinks we would be better off if we grew more drugs in algae, and fewer in Chinese Hamster Ovary cells.

We talk about why "monoclonal antibodies" are particularly safe and effective as drugs—but incredibly expensive to manufacture—and whether the fundamental problem of the biotech industry is that everyone just has too much money.

Full transcript at https://developmentandresearch.bio/episode/brian-finrow/